Theratechnologies Inc T.TH

New presentation

[SPCEO1]

It keeps improving with each iteration and it has come a very long way from where it was, so that is great. Most of the improvement has been through adding much more complete descriptions of the science, which is what US institutions are typcially looking for. 

Still, there is an unwillingness to highlight the valuation disparity between TH and other NASH stocks. Now that the have the FDA's backing for a phase III trial, I am not sure what would be a good reason for not including something that highlighted the rather massive gap between TH's valuation and that of other comparable companies. If I were a new portfolio manager seeing the TH presentation for the first time, I would certainly appreciate seeing those comparisons and they would make me very interested very quicky in TH's stock.

[SABBOBCAT]

If they highlight the valuation gap it will likely start to close and that would mean management doesn't get cheap options as part of their year end bonus. No rush in their mind to sell the stock until later in the spring.

[SPCEO1]

Of course, the NBF analyst is not giving any credit in his models or target price for the stock for NASH. Maybe the company can start by pointing out to the analyst that he is an outlier with regard to how most analysts value other companies NASH  opportunities.

[scarlet1967]

One would have hoped he would give credit to the R&D programs and a better PT after the offering well he got his commission and moving on to his next victim. I wouldn't be surprised if Ed Nash comes out with another stupid report too.

[SPCEO1]

Mackie and Canaccord at elast took a stab at including some info about the potential for NASH in their models. But they did not translate that into their target price, so we will see if they do that once they write something up. Neither has written anything since the news that the FDA had given TH the thumbs up on the NASH phase III, so they should start including something in their price targets

[juniper88]

NBF was one of the underwriters of the deal.  Would have been good if management had been able to point this out to NBF before agreeing to this deal.  Usually with these deals the Brokerages involved will write up a rosy review of the company.  We can't even get a fair review, let alone a rosy one.  

[qwerty22]

p4 "R&D engine of expert scientists" Basically Grinspoon (?) and what he might come up with re Tesamorelin.or they talking about the cancer group. Over-egging a little, some companies are genuine idea machines and that's  often what's behind high valuations for early stage companies, I wouldn't put THTX in that category though. Still it's intriguing, maybe

[scarlet1967]

From the good PR: "The final timing of the trial initiation is dependent upon any adjustments to the protocol and trial design as recommended by the FDA and European agencies. Any changes to the trial design or expected timelines based on discussions with the FDA will be disclosed thereafter."

[SPCEO1]

I thought the same thing when saw the R&D engine comments. Seems like a stretch. But TH has achieved a ton on both NASH and cancer with very little money spent, so the efficiency of that rather small engine is pretty high. Also, I don't think there will be a demand from the FDA to do anything other than a slightly altered phase III. Once they say pahse III, the bar should be pretty high